Building Biotech Series with Ainslie Little

Cell and gene therapies may well be some of the most important recent advancements in modern medicine. The way they work, however, is very complex and completely different from any pill that simply addresses symptoms. So who are the pioneers in this field and what dares them to ask “what if”? In this episode of the Building Biotechs podcast series sponsored by Thermo Fisher Scientific, learn from Ainslie Little, senior vice president of corporate strategy at BlueRock Therapeutics, how her company’s cell & gene platform is breaking new ground in this important space.